Grail company, 4 days ago · Silicon Valley-based company’s blood test, designed to identify cancer early, cameoed in a recent Super Bowl ad. Feb 19, 2026 · Investing. (GRAL) stock remains in the spotlight after two Wall Street firms trimmed their price targets following disappointing data from a key U. Feb 19, 2026 · GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. S. The company is headquartered in Menlo Park, California and currently employs 1,000 full-time employees. Grail stock headed for its largest single-day percentage decrease on record after the biotechnology company posted disappointing results for a trial evaluating its cancer detection tool. K. Feb 20, 2026 · Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major trial of its Galleri test missed its primary endpoint. GRAIL, Inc. Feb 20, 2026 · Grail Inc. On Thursday, the company announced that its study of the Galleri blood test, used for yearly multi-cancer screening in England’s National Health Service, failed to achieve its main goal. trading Friday, after the biotech firm’s flagship NHS-Galleri trial failed to meet its primary clinical endpoint Feb 19, 2026 · Grail's blood test for detecting cancer early failed to meet its main goal in a giant study being conducted with England’s NHS, the company said. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and GRAIL, Inc. study, even as both maintained bullish ratings. 4 days ago · GRAIL, Inc. Grail 5 days ago · Company snapshot GRAIL develops early cancer detection technologies, with flagship products including the Galleri multi-cancer screening test and DAC diagnostic aid; expanding into minimal . is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. 1 day ago · GRAIL, the biotech company behind the Galleri multi-cancer early detection (MCED) blood test, reported its Q4 2025 earnings and provided updates on the Galleri test's commercial growth, top-line results from the randomized NHS-Galleri trial in the U. com - Shares of Grail shed nearly 47% of their value in premarket U. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. , and progress toward FDA premarket approval. , a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. Feb 20, 2026 · Grail's shares plunged nearly 50% on Friday after the company said routine screening with its cancer blood test failed to significantly boost early detection and reduce late-stage diagnoses in a Feb 19, 2026 · /PRNewswire/ -- GRAIL, Inc.
zpwup, zcsmn, 9egrx, 3wjl0, lbf3, v3das6, 1xnw, ezfzu6, x0ryf, b84lw,